A randomized controlled trial of gemcitabine hydrochloride plus S-1 combination (GS) therapy and gemcitabine hydrochloride (Gem) therapy alone for patients with pancreatic cancer who are 75 years or older. - Gemcitabine and TS-1 Trial-2

ational Hospital Organization Shikoku Cancer Center0 个研究点目标入组 100 人开始时间: 2017年2月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients to whom gemcitabine hydrochloride plus nab-paclitaxel (brand name: Abraxane) can be introduced at the discretion of the attending doctor under consent of the patient. 2. Patients with active advanced multiple primary cancers with life expectancy within a half year. 3. Patients with a bacterial infection which requires systemic treatment by intravenous administration of antibiotic. 4. Patients with a complication of psychosis or psychiatric symptoms (including dementia) who are decided not suitable for participation in this study. 5. Patients who have undergone continuous systemic administration of steroids. 6. Patients with pulmonary fibrosis or interstitial pneumonia. 7. Patients with serious complications. 8. Patients with a complication of unstable angina or a history of myocardial infarction within 6 months. 9. Patients who require continuous administration of flucytosine, phenytoin and warfarin potassium. 10. Patients to whom neither iodine drug nor gadolinium can be used for drug allergy. 11. Patients for whom the principal investigator or other investigators decided not suitable for participation in this study.

发起方

ational Hospital Organization Shikoku Cancer Center